Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer

被引：0
作者：
Wehbe, TW [1 ]
Stein, BS [1 ]
Akerley, WL [1 ]
机构：
[1] RHODE ISL HOSP,DEPT UROL,PROVIDENCE,RI 02902
来源：
MAYO CLINIC PROCEEDINGS | 1997年 / 72卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Clinically significant responses after withdrawal of flutamide in patients with hormone-refractory prostate cancer (HRPC) are well documented. Failure to recognize this syndrome of response results in potential morbidity due to salvage therapy, confusion in interpretation of disease state, and introduction of a possible source of error in clinical trials, In this case report, we describe a patient with HRPC whose prostate-specific antigen levels decreased substantially in response to withdrawal of megestrol acetate. Such a response should be considered when megestrol acetate is used in the treatment of HRPC.
引用
收藏
页码：932 / 934
页数：3
相关论文
共 50 条
  • [31] The dynamics of prostate specific antigen in hormone refractory prostate carcinoma - An analysis of cancer and leukemia group B study 9181 of megestrol acetate
    Vollmer, RT
    Dawson, NA
    Vogelzang, NJ
    CANCER, 1998, 83 (09) : 1989 - 1994
  • [32] A novel prostate-specific adenovirus for gene expression in hormone-sensitive and hormone-refractory prostate cancer cells
    Cheng, WS
    Essand, M
    MOLECULAR THERAPY, 2004, 9 : S237 - S237
  • [33] Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer (vol 25, pg 3965, 2007)
    Armstrong
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) : 820 - 820
  • [34] Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! - In reply
    Armstrong, Andrew J.
    Garrett-Mayer, Elizabeth
    Eisenberger, Mario
    Tannock, Ian
    de Wit, Ronald
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (35) : 5674 - 5674
  • [35] Hormone-Refractory prostate cancer
    Rini B.I.
    Small E.J.
    Current Treatment Options in Oncology, 2002, 3 (5) : 437 - 446
  • [36] Hormone-refractory prostate cancer
    Alexandre, I.
    Rixe, O.
    ANNALES D UROLOGIE, 2007, 41 (02) : 47 - 55
  • [37] Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy
    Ross, RW
    Manola, J
    Hennessy, K
    Galsky, M
    Scher, H
    Small, E
    Kelly, WK
    Kantoff, PW
    CLINICAL CANCER RESEARCH, 2005, 11 (14) : 5195 - 5198
  • [38] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Marwan Ghosn
    Alain Dagher
    Fadi El-Karak
    The Journal of Biomedical Research, 2015, 29 (05) : 420 - 422
  • [39] Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient
    Ghosn, Marwan
    Dagher, Alain
    El-Karak, Fadi
    JOURNAL OF BIOMEDICAL RESEARCH, 2015, 29 (05): : 420 - 422
  • [40] Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer
    Furuya, Y
    Akimoto, S
    Akakura, K
    Igarashi, T
    Murakami, S
    Shimazaki, J
    Ito, H
    UROLOGIA INTERNATIONALIS, 1998, 60 (01) : 28 - 32
12345